What does Xilio Therapeutics, Inc. do?
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational,…
What is Xilio Therapeutics, Inc.'s P/E and P/B ratio?
Xilio Therapeutics, Inc. has a P/E ratio of -13.4 and a P/B ratio of 0.73.
What is Xilio Therapeutics, Inc.'s debt-to-equity ratio?
Xilio Therapeutics, Inc. has a debt-to-equity ratio of 0.09.
How much does Xilio Therapeutics, Inc. owe compared with what it owns?
Xilio Therapeutics, Inc. owes $0.53 for every $1 it owns (balance sheet Jun 2026), which is moderate.
What is Xilio Therapeutics, Inc.'s Positivity rank?
Xilio Therapeutics, Inc. is ranked #2,556 of 6,774 companies globally and #848 of 4,000 in United States on PositoAI, with a Positivity Score of 21,383.
Does Xilio Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Xilio Therapeutics, Inc..
Where can I read the latest news about Xilio Therapeutics, Inc.?
Recent headlines about Xilio Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Xilio Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Xilio Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.